Senate Finance To FTC: Address New PBM ‘Co-Manufacturing’ Practice

By Gabrielle Wanneh / October 1, 2024 at 6:54 PM

Senate Finance Chair Ron Wyden (D-OR) is pressing the Federal Trade Commission to address a new co-manufacturing practice by pharmacy benefit managers that he says thwarts generic drug competition, warning the commission that the drug chain middlemen are launching new business strategies just as FTC and lawmakers seek to stop PBMs’ traditional tactics.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.